Skip to main content

Stroke Survivors May Benefit From Yoga


July 27, 2012 — Eight weeks of modified yoga exercises led to clinically meaningful improvements in balance in a small pilot study of patients with a history of stroke who completed rehabilitative care. Yoga participants also experienced improvement in motor function, independence, and quality of life.
"Yoga is a mind-body approach and thus may fit well into rehab efforts and stroke recovery," Arlene A. Schmid, PhD, who led the study, told Medscape Medical News.
Dr. Arlene A. Schmid
"Rehabilitation therapists, such as occupational therapists [OTs], may consider embedding yoga into stroke rehab," added Dr. Schmid, a rehabilitation research scientist at the Roudebush Veterans Administration Medical Center and Indiana University in Indianapolis.
The study was published online July 26 in Stroke.
"Important Contribution"
Reached for comment, Maarten A. Immink, PhD, director of the Human Movement and Clinical Exercise Physiology program at the School of Health Sciences, University of South Australia, in Adelaide, said this report of post-stroke balance improvements with yoga "is an important contribution to a fledgling group of work that provides promising results in terms of the benefits of yoga for people who have had a stroke."
"The potential, as suggested by this set of preliminary studies, is that yoga might be an effective component of rehabilitation and long-term management approaches to promoting functional capacity, participation in activities of daily living, and quality of life," he added.
Dr. Schmid and colleagues studied 47 adults who had suffered stroke more than 6 months earlier who had completed all stroke-related rehabilitation and were able to stand with or without a device at the outset.
Nineteen were randomly allocated to twice-weekly group yoga for 8 weeks, 18 to yoga plus at-home yoga/relaxation audio recordings (yoga-plus group), and 10 to a wait-list control group. The yoga-plus group was included to incorporate standard clinical practice of home exercise prescription, the authors say. The 2 yoga groups were collapsed into a general yoga group for analyses.
The yoga classes were taught by a registered yoga therapist and included modified yoga postures, relaxation, and meditation. The classes grew more challenging each week. "We focused on hip and ankle range of motion and strength as we wished to improve balance," Dr. Schmid said. "We developed a standardized protocol, so everyone received the same intervention."
Researchers assessed balance with the Berg Balance Scale (BBS), balance self-efficacy with the Activities-Specific Balance Confidence Scale, fear of falling (FoF) with a dichotomous yes/no question, and quality of life with the Stroke-Specific Quality of Life Scale.
All yoga participants were physically able to do all planned yoga activities, and no injuries were sustained, the researchers say. Twenty-nine of the 37 completed all 8 weeks of the study (with post-assessments). Of the remaining 8 participants, 3 did not complete post-assessments, 4 attended 5 or fewer sessions, and 1 was hospitalized for reasons unrelated to the yoga classes.
The researchers say there were no significant changes in the variables of interest in the control group, but positive changes were seen in the yoga group, including a "clinically meaningful" improvement in balance.
After Bonferroni correction, BBS scores improved from 41.3 at baseline to 46.3 at 8 weeks (P < .001). BBS scores range from 0 to 56, with higher scores indicating better balance.
"Interestingly," say the researchers, there was even greater improvement for those with baseline balance impairment. The improvements in balance, they note, are "larger than what is typically found in the older adult yoga literature and thus indicate an opportunity for even more improvement for older adults with stroke-related balance impairments."
Less Fearful
At 8 weeks, fewer patients in the yoga group said they were worried or concerned about falling, and a significant increase was seen in the number of patients identified as "independent" on the modified Rankin Scale (mRS).
Effects on Fear of Falling and Functional Independence by Treatment
EndpointYogaControlP
Fear of falling, %5146< .001
Independent on mRS, %6857< .001
mRS, modified Rankin Scale.
A trend toward significant improvement in quality of life (P = .037) and toward balance self-efficacy (P = .035) was also noted.
Dr. Immink told Medscape Medical News that another recent study by his team suggests that the "mental health and perceived function of stroke patients can benefit from participation in yoga, which might be an important factor in yoga derived benefits for movement capacity and balance."
Dr. Schmid hopes to continue her studies of yoga post-stroke. "We have grants that are in review to support a larger study with more people, as well as including 8 weeks of yoga as we did here, but also 12 weeks of yoga to help understand the best frequency and duration of yoga as an aspect of post-stroke rehab," she told Medscape Medical News.
She noted that this study included only people with chronic stroke. "We do not know whether it is appropriate to do yoga during the more acute phases of stroke recovery."
"Although this is a small pilot study," added Dr. Immink, "it represents the largest study to date that evaluates the efficacy of yoga in a post-stroke population. The increasing uptake of yoga in society and in clinical applications, coupled with a set of work that supports the concept that yoga can benefit stroke patients, calls for well-funded, larger-scale trials of yoga for stroke patients."
The study was supported by the Veterans Administration. The authors have reported no relevant financial relationships.

Comments

Post a Comment

Popular posts from this blog

Antidepressants Linked to Higher Diabetes Risk in Kids

Pediatric patients who use antidepressants may have an elevated risk for type 2 diabetes, the authors of a new study report. In a retrospective cohort study of more than 119,000 youths 5 to 20 years of age, the risk for incident type 2 diabetes was nearly twice as high among current users of certain types of antidepressants as among former users, Mehmet Burcu, PhD, and colleagues report in an article  published online October 16 in  JAMA Pediatrics . The risk intensified with increasing duration of use, greater cumulative doses, and higher daily doses of these antidepressants. The findings point to a growing need for closer monitoring of these products, including greater balancing of risks and benefits, in the pediatric population, the authors caution. They undertook the study because, despite growing evidence of an association between antidepressant use and an increased risk for type 2 diabetes in adults, similar research in pediatric patients was scarce. "To our know...
Post a Comment
Read more

Contact Precautions May Have Unintended Consequences

Contact precautions, including gloves, gowns, and isolated rooms, have helped stem the transmission of hospital pathogens but have also had some negative consequences, according to findings from a new study. Healthcare worker (HCWs) visited patients on contact precautions less frequently than other patients and spent less time with those patients when they did visit, report Daniel J. Morgan, MD, from the University of Maryland School of Medicine and the Veterans Affairs (VA) Maryland Health Care System, Baltimore, and colleagues. Moreover, patients on contact precautions also received fewer outside visitors. "Less contact with HCWs suggests that other unintended consequences of contact precautions still exist," Dr. Morgan and coauthors write. "The resulting decrease in HCW contact may lead to increased adverse events and a lower quality of patient care due to less consistent patient monitoring and poorer adherence to standard adverse event prevention methods (such...
Post a Comment
Read more

Missing Data Lead FDA Panel to Vote Against Rivaroxaban for ACS May 23, 2012 (Updated May 24, 2012) (Silver Spring, Maryland) — The missing data issues plaguing the ATLAS ACS 2 TIMI 51 trial of the factor Xa inhibitor rivaroxaban (Xarelto, Bayer Healthcare/Janssen Pharmaceuticals) have prevented the drug from earning the endorsement of the FDA Cardiovascular and Renal Drugs Advisory Committee. At its May 23 meeting, the panel voted six to four (with one abstention) against recommending that the FDA approve rivaroxaban for reducing the risk of thrombotic cardiovascular events in patients with acute coronary syndrome or unstable angina in combination with aspirin, aspirin plus clopidogrel, or ticlopidine. Janssen's application is based on the results of the ATLAS ACS 2 phase 3 and the ATLAS ACS TIMI 46 phase 2 trial. The placebo-controlled ATLAS ACS 2 showed rivaroxaban reduced the risk of both all-cause and cardiovascular mortality while increasing the risk of bleeding and intracranial hemorrhage, but the studies were hindered by early patient withdrawals and missing data. We Don't Know What We're Missing Based on the ATLAS ACS 2 results, FDA reviewer Dr Karen Hicks recommended approval of rivaroxaban for the requested indications except all-cause mortality. However, another FDA reviewer, Dr Thomas Marciniak, was adamant that the trial results are not interpretable because about 12% of the patients had incomplete follow-up, far higher than the 1% to 1.5% differences in the end-point rates between rivaroxaban and placebo. A total of 1294 subjects discontinued the trial prematurely, and the company was only able to contact 183, of which 177 were confirmed to be alive. Because of the patient dropouts, the company adopted a "modified intention-to-treat analysis," whereby patients were observed for 30 days after randomization or the global end date for the trial, instead of observing all the patients until the end of the trial as the FDA originally suggested. Marciniak criticized the sponsor's efforts to follow the patients and said that three patient deaths not counted in the modified intention-to-treat analysis may just be the "tip of the iceberg." Because the percentage of patients whose ultimate vital status remains unknown is much greater than the reported differences in mortality rates, the claimed mortality benefits are not reliable. The majority of the panel sided with Marciniak. For example, Dr Sanjay Kaul (University of California, Los Angeles) voted "no" because "there was enough uncertainty in the quality and robustness of the data that dissuaded me from voting yes. . . . The 'missingness' of the data doesn't invalidate it, but it certainly makes it hard to infer [the conclusion]." Dr Steven Nissen (Cleveland Clinic, OH) said that the decision to use the modified intention-to-treat analysis had a "profound impact" on the interpretability of the data. "It's saying we don't care what happens after 30 days, [and] that colored the trial in ways we couldn't recover from." Given the risk of major bleeding, "I want to see better evidence that this strategy of adding an Xa inhibitor or a direct thrombin inhibitor or something else to a good antiplatelet agent is robustly better for the patient," Nissen said. He recommends that the companies run a new trial of the 2.5 twice-daily dose of rivaroxaban using a strict intention-to-treat approach, but, he said, "I don't expect the death benefit to be too robust." Several panelists said they were concerned that the patients who dropped out of the trial were disproportionately likely to have a bleeding event, which led them to quit the trial, or a "protopathic" event, as statistician Dr Scott Emerson (University of Washington, Seattle) put it. "We're worried that an impending event is what is changing their behavior. We see that all the time in clinical trials--that regularly measured end points do not pick up [all of] the events," he said. He said that since the company was only able to contact 183 of the over 1200 patients who dropped out, it is possible that the dropouts skew the outcomes comparison of the trial. "Differential event rates after dropout are the number-one thing we're afraid of, so you have to explore it" in a statistical sensitivity analysis of the potential impact of these unknown outcomes. "It would not surprise me if, at the end of the day, these data did not hold up under a proper sensitivity analysis," he said. "What I want to know is, among the people who had events, how differential was the follow-up, but I can tell you by just looking at it, there was a very slightly different amount of follow-up of the people in the treatment arm. But I don't know whether everyone in the treatment arm was cured and they were trekking in the Himalayas and everyone in the placebo arm went home to die. I don't know that that's not the case." Dr Maury Krantz (University of Colorado, Denver) voted in favor of approval but said he does not know how rivaroxaban would perform in general clinical practice, especially when used with aspirin and clopidogrel. "I felt very much torn by this. This isn't a simple paradigm shift. It means going to triple therapy, which is really a three-headed monster in many ways. I think that what you're going to see in practice, if this is not done carefully with the proper labeling and secondary studies, is really dramatic magnification of bleeding and perhaps minimization of the efficacy benefit."

May 23, 2012   (Updated May 24, 2012)  (Silver Spring, Maryland)  —  The missing data issues plaguing the  ATLAS ACS 2 TIMI 51   trial of the factor Xa inhibitor  rivaroxaban  (Xarelto, Bayer Healthcare/Janssen Pharmaceuticals) have prevented the drug from earning the endorsement of the  FDA  Cardiovascular and Renal Drugs Advisory Committee. At its May 23 meeting , the panel voted six to four (with one abstention) against recommending that the FDA approve rivaroxaban for reducing the risk of thrombotic cardiovascular events in patients with acute coronary syndrome or unstable angina in combination with aspirin, aspirin plus  clopidogrel , or  ticlopidine . Janssen's application is based on the results of the ATLAS ACS 2 phase 3 and the  ATLAS ACS TIMI 46   phase 2 trial. The placebo-controlled ATLAS ACS 2 showed rivaroxaban reduced the risk of both all-cause and cardiovascular mortality while increasing the ri...
Post a Comment
Read more